All contents ©2010 ALP Life Sciences, LLC. All rights reserved.
Use of this site signifies acceptance of Terms and Conditions
Use of this site signifies acceptance of Terms and Conditions
ALP Life Sciences, LLC, founded in 2008, is a life sciences research and development company targeting fatty liver related diseases. The Company is focused on therapeutics, diagnostics and drug metabolism testing utilizing the emerging science of Applied Lipid Polymorphism. Nanoveson™ is the first therapy pursued for commercialization by the Company.
The current research on the proposed mechanisms of action of Nanoveson™ and details of the biochemistry cascade it produces are presented in the Nanoveson™ whitepaper. Treatment for non-alcoholic fatty liver diseases (NAFLD), is the first indication target, but Nanoveson™ also has the potential to treat other liver diseases and multiple related diseases. Nanoveson™ has potential to generate biomarkers for diagnostic tests for NAFLD and other liver diseases and related diseases. Nanoveson™ potentially offers a new and effective approach to drug metabolism testing, for which there is a significant commercial need. Nanoveson™ triggers the polymorphism of triglyceride stores in the liver into phospholipids in bile. By increasing phospholipid concentration and dropping pH in the intestines, the therapy triggers the fusion and aggregation of lipid membranes, producing micelles and vesicles in the intestines, and their aggregation into large lipid structures for elimination.
The Nanoveson™ therapy mechanisms of action may treat inflammatory diseases, including asthma, arthritis, cardiovascular diseases, gastrointestinal diseases, diabetes and cancer by targeting and improving enterohepatic circulation, which is how the body maintains whole body quantitative homeostasis of arachidonic acid. Arachidonic acid metabolism is implicated in many inflammatory diseases along multiple pathways. Orphan disease indication targets may be pursed through clinical trials focused on arachidonic acid specific surrogate end points.
ALP Life Sciences, LLC is currently evaluating strategic relationships in the areas of principal investigators, clinical trial centers, manufacturing, commercialization, and global licensing and partnering opportunities for development of therapy, diagnostics and drug metabolism testing. Clinical research and funding relationships with public institutes of health will be pursued. Funding relationships with medical research foundations and life sciences venture capital firms are also being evaluated. Interested parties should contact ALP Life Sciences, LLC. The Nanoveson™ whitepaper is available at www.ALPLifeSciences.com/wp.